FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to genetic engineering, molecular biology and medicine. A method for enhancing the expression of NGN3 and NKX6.1 and in a population of cells expressing markers characteristic of the pancreatic endocrine line. The method comprises culturing isolated pluripotent human embryonic stem cells derived from stable lines of human embryonic stem cells (line H1, H7 or H9). The method comprises differentiating the isolated pluripotent stem cells into a definitive endoderm cell line by treatment with medium supplemented with TGF-β receptor agonist. The method comprises differentiating the cell line into a definitive endoderm pancreatic endoderm cell line by culturing in a medium supplemented with a compound selected from the group: H-9, H-89, GF 109203X, HA-1004, PP2, PP1, SB-203580, SB-202190, Tyrphostin 25, Tyrphostin AG1478, Tyrphostin 46, GW 5074, hydroxyl-2-naphthalenylmethylphosphonic acid, AG490, Y-27 632 and ML-7. The method comprises differentiating the pancreatic endoderm cell line into cells of the pancreatic endocrine line by culturing with Noggin.
EFFECT: method increases the expression of NGN3 and NKX6.1 compared to cells that are not treated with said compound.
2 cl, 8 tbl, 3 ex
